Importantly, CD19-targeted 17-DMAG nanoparticles, either combined with the BCR-ABL1-targeted TKI imatinib or the broad-spectrum TKI ponatinib 51, 52, not only reduced tumor burden but also significantly enhanced T-cell immunity in BCR-ABL1+ B-ALL. The gene discussed is CD19; the disease is neoplasm.